☆ 4.2 Article

Collective Expert Perspectives on the Use of Safinamide as Adjunctive Therapy for Parkinson's Disease: Online-Based Delphi Survey

PARKINSONS DISEASE (2022)

Related references

Note: Only part of the references are listed.

Review Clinical Neurology

Risk factors of impulsive-compulsive behaviors in PD patients: a meta-analysis

Lanxiao Cao et al.

Summary: This meta-analysis indicates that males, young age, early disease onset, long disease duration, depression, levodopa dosage, dopamine receptor agonists, and amantadine are risk factors for impulsive-compulsive behaviors in Parkinson's disease patients.

JOURNAL OF NEUROLOGY (2022)

Add to Collection

Article Clinical Neurology

Safinamide improves sleep and daytime sleepiness in Parkinson's disease: results from the SAFINONMOTOR study

Diego Santos Garcia et al.

Summary: The study found that after 6 months of treatment with safinamide, PD patients experienced improvements in sleep quality and daytime sleepiness.

NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Characteristics of wearing-off and motor symptoms improved by safinamide adjunct therapy in patients with Parkinson's disease: A post hoc analysis of a Japanese phase 2/3 study

Masahiro Nomoto et al.

Summary: This study analyzed the response of patients with Parkinson's disease to safinamide treatment. The results showed that safinamide improved major motor symptoms at different doses and was related to baseline non-motor symptoms.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2022)

Add to Collection

Article Clinical Neurology

Overnight switch from rasagiline to safinamide in Parkinson's disease patients with motor fluctuations: a tolerability and safety study

F. Stocchi et al.

Summary: The study demonstrates that overnight switch from rasagiline to safinamide is safe and well tolerated by patients, without causing serotonin syndrome or hypertensive crisis. Short-term substitution of these two drugs did not result in adverse effects on blood pressure in most patients.

EUROPEAN JOURNAL OF NEUROLOGY (2021)

Add to Collection

Article Clinical Neurology

Safinamide improves executive functions in fluctuating Parkinson's disease patients: an exploratory study

Domiziana Rinaldi et al.

Summary: Safinamide, as a monoamine-oxidase-B inhibitor, has shown positive effects on executive functions in Parkinson's disease patients, improving attention and inhibition of cognitive interference. Add-on treatment with safinamide significantly increases scores on FAB, SWCT, and UPDRS-III, particularly enhancing motor programming and mental flexibility.

JOURNAL OF NEURAL TRANSMISSION (2021)

Add to Collection

Article Neurosciences

SURINPARK: Safinamide for Urinary Symptoms in Parkinson's Disease

Ana Gomez-Lopez et al.

Summary: A retrospective study found that the use of Safinamide significantly improves urinary symptoms in patients with Parkinson's disease, particularly urgency, incontinence, frequency, and nocturia, providing a treatment option for patients.

BRAIN SCIENCES (2021)

Add to Collection

Article Clinical Neurology

Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study

Yoshio Tsuboi et al.

Summary: Safinamide as an adjunct to levodopa may alleviate pain in patients with Parkinson's disease, especially during wearing-off periods. Patients with moderate-to-severe bradykinesia and early-morning dystonia may benefit more from safenamide treatment during the OFF phase.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2021)

Add to Collection

Article Neurosciences

Safinamide Improves Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study

Diego Santos Garcia et al.

Summary: The study demonstrates that safinamide is effective in improving non-motor symptoms burden in Parkinson's disease patients, including sleep, mood, memory, etc., and can improve patients' quality of life.

BRAIN SCIENCES (2021)

Add to Collection

Article Behavioral Sciences

Selegiline reduces daytime sleepiness in patients with Parkinson's disease

Marco Gallazzi et al.

Summary: The study found that the use of selegiline improved excessive daytime sleepiness in Parkinson's disease patients significantly, but did not change the evaluation of disease severity. Therefore, selegiline may be a valuable add-on therapy to reduce daytime somnolence in PD patients.

BRAIN AND BEHAVIOR (2021)

Add to Collection

Article Clinical Neurology

Switch from rasagiline to safinamide in fluctuating Parkinson's disease patients: a retrospective, pilot study

Edoardo Bianchini et al.

Summary: Switching PD patients from rasagiline to high-dose safinamide may provide more powerful benefits in fluctuating PD patients, significantly reducing subjective symptoms of wearing-off without any reported adverse events.

NEUROLOGICAL RESEARCH (2021)

Add to Collection

Article Clinical Neurology

Efficacy and safety of safinamide as an add-on therapy to L-DOPA for patients with Parkinson's disease: A randomized, double-blind, placebo-controlled, phase II/III study

Nobutaka Hattori et al.

PARKINSONISM & RELATED DISORDERS (2020)

Add to Collection

Article Clinical Neurology

Long-term safety and efficacy of safinamide as add-on therapy in levodopa-treated Japanese patients with Parkinson's disease with wearing-off: Results of an open-label study

Yoshio Tsuboi et al.

JOURNAL OF THE NEUROLOGICAL SCIENCES (2020)

Add to Collection

Article Pharmacology & Pharmacy

Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia

Michele Morari et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)

Add to Collection

Article Medicine, General & Internal

Developing consensus among movement disorder specialists on clinical indicators for identification and management of advanced Parkinson's disease: a multi-country Delphi-panel approach

Angelo Antonini et al.

CURRENT MEDICAL RESEARCH AND OPINION (2018)

Add to Collection

Article Clinical Neurology

Rasagiline improves polysomnographic sleep parameters in patients with Parkinson's disease: a double-blind, baseline-controlled trial

W. Schrempf et al.

EUROPEAN JOURNAL OF NEUROLOGY (2018)

Add to Collection

Letter Clinical Neurology

Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study

Claudio Liguori et al.

PARKINSONISM & RELATED DISORDERS (2018)

Add to Collection

Article Clinical Neurology

Assessment of Safety and Efficacy of Safinamide as a Levodopa Adjunct in Patients With Parkinson Disease and Motor Fluctuations A Randomized Clinical Trial

Anthony H. V. Schapira et al.

JAMA NEUROLOGY (2017)

Add to Collection

Review Clinical Neurology

Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease - Clinical practice recommendations

Claudia Trenkwalder et al.

PARKINSONISM & RELATED DISORDERS (2015)

Add to Collection

Article Clinical Neurology

Two-Year, Randomized, Controlled Study of Safinamide as Add-on to Levodopa in Mid to Late Parkinson's Disease

Rupam Borgohain et al.

MOVEMENT DISORDERS (2014)

Add to Collection

Article Pharmacology & Pharmacy

The Effect of Safinamide, a Novel Drug for Parkinson's Disease, on Pressor Response to Oral Tyramine: A Randomized, Double-Blind, Clinical Trial

A. Marquet et al.

CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)

Add to Collection

Article Clinical Neurology

Management of punding in Parkinson's disease: an open-label prospective study

A. Fasano et al.

JOURNAL OF NEUROLOGY (2011)

Add to Collection

Article Pharmacology & Pharmacy

Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers

Andrea Francesco Daniele Di Stefano et al.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2011)

Add to Collection

Article Clinical Neurology

Pathological Gambling in Parkinson Disease Is Reduced by Amantadine

Astrid Thomas et al.

ANNALS OF NEUROLOGY (2010)

Add to Collection

Article Clinical Neurology

Parkinson's Disease Symptoms: The Patient's Perspective

Marios Politis et al.

MOVEMENT DISORDERS (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.